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Since redox active metals are often transported across membranes into cells in the reduced state, we have investigated whether exogenous ferri-
heme or heme bound to hemopexin (HPX), which delivers heme to cells via receptor-mediated endocytosis, interact with a cell growth-associated
plasma membrane electron transport (PMET) pathway. PMET reduces the cell-impermeable tetrazolium salt, WST-1, in the presence of the
mandatory low potential intermediate electron acceptor, mPMS. In human promyelocytic (HL60) cells, protoheme (iron protoporphyrin IX; 2,4-
vinyl), mesoheme (2,4-ethyl) and deuteroheme (2,4-H) inhibited reduction ofWST-1/mPMS in a saturablemanner supporting interactionwith a finite
number of high affinity acceptor sites (Kd 221 nM for naturally occurring protoheme). A requirement for the redox-active iron was shown using
gallium-protoporphyrin IX (PPIX) and tin-PPIX. Heme–hemopexin, but not apo-hemopexin, also inhibited WST-1 reduction, and copper was
required. Importantly, since neither heme nor heme–hemopexin replace mPMS as an intermediate electron acceptor and since inhibition of WST-1/
mPMS reduction requires living cells, the experimental evidence supports the view that heme and heme–hemopexin interact with electrons from
PMET. We therefore propose that heme and heme–hemopexin are natural substrates for this growth-associated electron transfer across the plasma
membrane.
© 2007 Elsevier B.V. All rights reserved.Keywords: PMET; Heme; Hemopexin; Plasma membrane electron transport; Oxidoreductase1. Introduction
Proliferating mammalian cells transfer electrons across the
plasma membrane from intracellular reductants like NADH to
extracellular electron acceptors such as oxygen [1–3]. These
plasma membrane electron transport (PMET) systems facilitate
cellular responses to physiological stimuli and have been
implicated in the activation of signaling cascades and in the
control of cell growth [4,5]. At least two PMET pathways have
been shown to be associated with cell growth. One reduces
ferricyanide [6] and has been shown to use the voltage-
dependent anion channel, VDAC1 [1]. The other is comprised
of at least three components, involves plasma membrane ubi-
quinone [7,8], and oxygen can be a terminal electron acceptor
[9]. This PMET pathway has been shown to be quite distinct
from mitochondrial electron transport [10] and recycles cyto-⁎ Corresponding author. Tel.: +1 816 235 2579; fax: +1 816 235 5595.
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in glycolytic cells [9]. It is measured by reduction of the water
soluble tetrazolium salt, WST-1 [2,(4-iodophenyl)-3-(4-nitro-
phenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium), in the presence
of an intermediate electron acceptor [IEA; mPMS (1-methoxy-
5-methylphenazinium methylsulfate)]. The standard 1 electron
reduction potential of mPMS is +70 mV and of WST-1 is
−141mV (obtained by adding +199mV to−340mVversus Ag/
AgCl and saturated KCl, [11]). The IEA accepts electrons from a
terminal electron donor enzyme in the pathway to reduceWST-1
directly (Figs. 1A and B; ref. [12]). WST-1 contains negatively
charged sulfonate moieties, excluding it from the cell via the
plasma membrane potential (50–70 mV, negative inside) but
allowing it to accept electrons from mPMS [11,12]. Activated
mPMS will pick up low potential electrons from plasma mem-
brane electron donors to reduce WST-1 directly in two separate
one electron transfer events involving both WST-1 and extra-
cellular PMS radicals [M.V. Berridge, M. Davies, unpublished
data]. A requirement for ubiquinone (standard one electron
Fig. 1. Reduction of cell-impermeable WST-1 by plasma membrane electron transport. Panel A: diagrammatic representation of WST-1 reduction involving the
intermediate electron acceptor, mPMS, (modified from information provided by Roche Diagnostics GmbH). Panel B: current model of PMET from intracellular
NADH to extracellular WST-1: model of sites of interaction of heme with PMET. Diagram of ubiquinone-dependent electron transfer across the plasma membrane
based on experimental evidence (for recent review see ref. [8]). Electrons are transferred (dotted line) from cytosolic NADH via ubiquinone (Q), shown as the radical
semiubiquinone, via membrane protein components of PMET to the intermediate electron acceptor mPMS generating the mPMS radical, which then reduces WST-1.
Two electrons and a proton are required to reduce WST-1. Two possible sites of interaction of either heme or heme–hemopexin with the electron path for WST-1
reduction are indicated by the schematic heme molecule shown. Panel C: Structures of porphyrin and heme analogs used. (i) Protoheme {2,4-vinyl, protoH; iron
protoporphyrin IX chloride}; (ii) mesoheme {2,4,-ethyl, mesoH; iron mesoporphyrin IX chloride; 8,13-Bis(ethyl)-3,7,12,17-tetramethyl-21H,23H-porphine-2,18-
dipropionic acid iron (III) chloride}; (iii) gallium-protoporphyrin (GaPP); (iv) tin-protoporphyrin (SnPP); (v) iron-deuteroporphyrin IX dimethyl ester (2,4,-H, dH-
ester; ); (vi) protoporphyrin IX {PPIX; 8,13-Bis(vinyl)-3,7,12,17-tetramethyl-21H,23H-porphine-2,18-dipropionic acid}; and (vii) deuteroporphyrin IX {2,4,-H,
dPIX; 3,7,12,17-Tetramethyl-21H,23H-porphine-2,18-dipropionic acid}. Not shown is deuteroheme (2,4,-H, deuteroH). Some tetrapyrroles are supplied from Frontier
Scientific as the mono or dichloride as shown.
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[13,14], has been confirmed genetically in yeast [15]. Further-
more, a complex of proteins in the plasma membrane that
includes a constitutively expressed NADH-dependent oxidase
(CNOX)-like member of the ECTO-NOX family of cell surface
oxidases has been shown to be involved in the NADH-
dependent reduction of WST-1 [16]. Although oxygen can be
reduced by these NOX-like surface oxidoreductases [9], the
efficiency is poor and other natural substrates remain to be
identified.
Redox-active metals like iron and copper are often trans-
ported in the reduced state, [17,18] with the transporters beingassociated with metal reductases. In duodenal enterocytes, cyto-
chrome b (Dcytb) has been proposed to reduce dietary ferric iron
for iron absorption via transport across the basolateral membrane
by the divalent metal transporter, DMT1 [19]. In erythroid cells,
another ferri-reductase, Steap3, related to the F(420)H(2):
NADP+ oxidoreductases and yeast FRE metallo-reductases,
acts in concert with diferric-transferrin generating Fe(II) as
the exported species from endosomes [20]. In several cell
types including macrophages and enterocytes, iron export from
cells utilizes the multi-copper oxidase, hephaestin, together
with the Fe(II) exporter, ferroportin, for iron loading of trans-
ferrin (for recent reviews see ref. [21,22]). Transporters for
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or related macrocycles) have been described, e.g. heme carrier
protein-1 (HCP1 [23], FLVCR [24], ABCG2 [25] and ABCB6
[26]; but neither their mechanism(s) nor the transported species
have been defined. (The low capacity, pH-independent HCP1
was recently shown to have a principle function in proton-
coupled folate transport [27]). Because heme, like iron, is more
soluble in the reduced state, ferroheme is likely to be a trans-
ported species. Furthermore, the redox potential, E1/2, of heme
determined by spectroelectrochemistry is relatively low (proto-
heme−70mV) and is increased by coordination of the heme iron
with imidazole in solution (protoheme(imidazole)2 is +10 mV;
[28]) or with two histidine residues in the glycoprotein
hemopexin (HPX; +45 mV for protoheme-HPX with KCl;
Flaherty, M., Smith, A. and Crumbliss, A., manuscript
submitted). The E1/2 of heme–hemopexin (1:1 molar ratio) is
+65 mV by potentiometry [29] and +88 mV by spectro-electro-
chemistry with NaCl (Flaherty, M., Smith, A. and Crumbliss, A.,
manuscript submitted). These redox potentials place heme and
heme–hemopexin in a position to accept electrons from PMET,
likely via ubiquinone and, thus, compete withWST-1/mPMS for
electrons from PMET (see Fig. 1B). PMET is poorly active in
non-dividing cells but highly active in rapidly dividing HL60
Rho0 cells that lack functional mitochondrial electron transport
[30]. We therefore investigated whether exogenous heme or
heme–hemopexin are substrates for cell growth-associated
PMET using exponentially-growing human promyelocytic
HL60 cells. These cells express hemopexin receptors [31] and
respond to heme–hemopexin with induction of HO-1 mRNA
[32], a process that requires heme uptake [33].2. Materials and methods
2.1. Chemicals and reagents
Metalloporphyrins and porphyrins (see Fig. 1C for structures) were obtained
from Frontier Scientific (Logan, UT) and their concentrations determined
spectrophotometrically in dimethylsulfoxide (DMSO) or other appropriate
solvents. For dimethyl sulfoxide (DMSO) the millimolar extinction coefficients
(EmM) are: protoheme {hemin; iron-protoporphyrin IX chloride; 2,4-vinyl; see
Fig. 1} at OD406 EmM=170; mesoheme (iron-mesoporphyrin IX chloride; 2,4-
ethyl) at OD394 EmM=170; deuteroheme (iron-deuteroporphyrin IX; 2,4-H) at
OD392 EmM=170; GaPP (gallium protoporphyrin IX chloride) at OD413
EmM=249; deuteroporphyrin IX at OD398 EmM=433. The concentration of
DMSO stocks of the heme analog, tin protoporphyrin IX chloride (SnPP) is
determined from an aliquot in 0.5% pyridine with 1 drop NH4OH/ 100 mL
(OD406 EmM=164) and of protoporphyrin IX in 1.5 M HCl (OD408
EmM=297). The concentration of Fe(III) deuteroporphyrin IX dimethyl ester
chloride was determined gravimetrically (MW=628.3). Two solvents for heme
and mesoheme were compared: DMSO or buffer (i.e. solubilization in strong
alkali. 1 M NaOH, pH 11, followed by dilution in sodium phosphate buffer, pH
7.4). Iscove's Modified Dulbecco's Medium was purchased from American
Type Culture Collection (ATCC; Manassas, VA). Fetal bovine serum (FBS),
penicillin/streptomycin, and Hanks' Balanced Salt Solution (HBSS) were
obtained from Invitrogen Corporation (Carlsbad, CA). The WST-1 (2,(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) reagent is
supplied by Roche Diagnostics Corporation (Indianapolis, IN) in a mixture with
the IEA, mPMS (1-methoxy-5-methylphenazinium methylsulfate). For certain
investigations, pure WST-1 was obtained from Dojindo Laboratories (Kuma-
moto, Japan). All other chemicals were obtained either from Sigma Chemical
Co. (St. Louis, MO) or from Fisher Scientific Co. (Pittsburg, PA).2.2. Cell culture
HL60 cells were obtained from ATCC and cultured in Iscove's Modified
Dulbecco's Medium supplemented with 20% FBS and 1% penicillin/
streptomycin under conditions recommended by ATCC (i.e. maintained at
densities of 1×105 and 1×106 cells/mL for exponential growth), at 37 °C in a
humidified incubator with 5% CO2. Minimal deviation hepatoma cells (Hepa),
derived from the mouse solid tumor BW 7756, were grown in DMEM
supplemented with 2% FBS and 0.5% gentamicin as previously described [34].
2.3. WST-1 reduction
The reduction of WST-1 in the presence of mPMS was measured spectro-
photometrically at 450 nm using a 96-well plate reader following a published
protocol [3] but with some modifications. Briefly, HL60 cells were harvested,
gently washed in HBSS, resuspended in HBSS and seeded (50 μl) in 96-well
plates at a cell density of 7×105 cells/ well into HBSS. Porphyrin or metallo-
porphyrins or appropriate solvent was added to the cells at the indicated con-
centrations (final assay volume 200 μl) followed by incubation in a 37 °C water
bath for 10 min. The tetrapyrrole solvent DMSOwas used only at concentrations
less than 0.25% v/v because higher levels (e.g. 0.3–1% v/v) inhibited WST-1
reduction. Presumably DMSO perturbs membrane protein–lipid interactions
altering electron transfer through PMET. Next, either WST-1/mPMS (10 μL of
Roche reagent containing 500 μMWST-1) or HBSS (solvent control) was added
followed by a further incubation for 45 min at 37 °C. The plate was cooled at RT
for 5 min before recording the absorbance at 450 nm. The reduction of WST-1
was calculated from the differences in the absorbance of media in wells where
cells had been incubated with metalloporphyrins or heme analogs (or solvent)
together with WST-1/mPMS after subtraction of the absorbance of cells
incubated with metalloporphyrins or heme analogs or solvent in the presence
or absence of WST-1/mPMS. WST-1/mPMS reduction by cells is linear under
these conditions over the time period of 45 min. The PMETassay was carried out
in triplicate and 2–12 independent experiments as described in the figure legends.
The data shown are mean±S.E.M. Statistical analyses used PRISM 5.0 (Graph
Pad Software Incorporated, San Diego, CA), using an unpaired t-test with
confidence interval of 95% and P values are 2-tailed.
For experiments with heme–hemopexin, HL60 cells (7×105 cells/ well in
HBSS) were incubated with either heme–hemopexin, or as a negative control
apo-hemopexin (HPX) or PBS at the indicated concentrations (calculated from
published extinction coefficients [35]) in a 37 °C water bath for 10 min followed
by addition of either WST-1/mPMS (10 μL) or HBSS (10 μL) and reduction of
WST-1 measured 45 min later. For experiments with heme or heme–hemopexin
in the presence or absence of the copper chelator bathocuproine disulfonic acid
(BCDS), BCDS (10 μM in water) was added to the cells which were then
incubated for 10min in a 37 °Cwater bath. heme–hemopexin or heme (or PBS or
DMSO, respectively, as solvent controls) was then added to the cells at the
indicated concentrations and the cells were incubated for a further 10 min in a
37 °C water bath. The volume of heme–hemopexin or heme added to the cells
was kept constant for all concentrations. After this incubation, either 10 μLWST-
1/mPMS or HBSSwas added to the cells followed by a further 45 min incubation
and measurement of WST-1 reduction.
To determine whether the tetrapyrroles or heme–hemopexin affected the
reduction ofWST-1/mPMS (23.8 μMWST-1 Roche reagent) by NADH (40 μM)
in the absence of cells the following samples were set up using the final
concentrations of reagents used in the cell PMET assay and tetrapyrroles (at 0.1,
0.25, 0.5, 1.0, 1.5, 2.0 and 5.0 μM) or heme–hemopexin (at 0.5, 1.0, 2.5, 5.0, 10
and 15 μM). Four samples (1.0 ml final volume) were set up in the following
order of addition: HBSS+DMSO/PBS+WST-1 /mPMS+H2O (A); HBSS+
DMSO/PBS+WST-1/mPMS+NADH (B); HBSS+ tetrapyrroles /HHPX+
WST-1/mPMS+NADH (C) and HBSS+tetrapyrroles /HHPX+WST-1/mPMS+
H2O (D). Reduction by NADH was complete within 1 min and spectra recorded
on a HP 8452A spectrophotometer in a cuvette with a 1-cm light path. For each
concentration of tetrapyrrole or heme–hemopexin, spectrum A was subtracted
from spectrum B (control set); and spectrumD from spectrum C (tetrapyrrole set).
Then the subtracted tetrapyrrole or heme–hemopexin spectrum was compared
with its subtracted control spectrum at each concentration. The O.D. 450 nm for
either the tetrapyrrole or heme–hemopexin data set was plotted as a percentage of
the O.D. 450 nm from its control data set. Each experiment was repeated at least
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immediately after the HBSS in samples B and C.
3. Results
3.1. Effect of protoheme and mesoheme on WST-1/mPMS
reduction
To investigate whether exogenous heme interacts with the
PMET pathway that reduces WST-1/mPMS, human promyelo-
cytic HL60 cells were first incubated for 10 min with varying
concentrations (0.1 μM–5 μM) of either protoheme [iron
protoporphyrin IX; 2,4-vinyl] or the heme analog mesoheme
[iron mesoporphyrin IX; 2,4,-ethyl] in DMSO before adding
WST-1/mPMS and measuring WST-1 reduction spectrophoto-
metrically.When cells were incubated withWST-1/mPMS, there
was extensive reduction of WST-1 and this PMET activity was
significantly decreased by∼75% by either proto- or meso-heme,
but not by the solvent control (b0.25% DMSO; Fig. 2A). If the
IEA mPMS was omitted, there was no reduction of WST-1 and
importantly, heme could not substitute for mPMS to facilitate
WST-1 reduction (Fig. 2A). This inhibition by heme/DMSOwas
saturable at low concentrations (0.5–1.0 μM) suggesting a finite
number of events, likely at cellular sites with relatively high
affinity for the heme (discussed further below). Evidence indi-
cates that the source of reducing equivalents for WST-1 re-
duction is NADH derived from the mitochondrial citric acid
cycle [12]. When NADH is added to WST-1 in the presence of
mPMS but in the absence of cells, dye reduction is rapid and
extensive (e.g. O.D. 450 nm increases from 0.08 to 1.02 in 30 s;
ref. [36]). To demonstrate that the extensive inhibition of WST-
1/mPMS reduction by heme requires viable cells, additional
controls were carried out in a cuvette. There was no significant
change in the absorbance at 450 nm following heme (0.1–2 μM)
addition to the other reagents in the absence of cells, and when
NADH was added last (Fig. 2B, LHS panel). Heme does not
substitute as an intermediate electron acceptor for WST-1 re-
duction. In the absence of cells, a small inhibition was observed
at 5 μM heme, which was significantly less than the extensive
decrease seen in the presence of cells. If the Kd for this inter-
action of protoheme with cells is taken as half maximal inhibi-
tion of WST-1/mPMS reduction, after subtracting the “no cells”
data from “live cells” data in Fig. 2A, the Kd is 221 nM (using a 1
site binding hyperbola R2 =0.9286, Fig. 2B, RHS panel).
Overall, these observations provide strong evidence that both
proto- and meso-heme interact with electrons derived from cells.
3.2. Investigation of structural requirements for the inhibitory
effects of heme on PMET
The physical state of metallo-porphyrins (i.e. heme and heme
analogs) and porphyrins is greatly affected by solvent. Spectral
data reveal that heme in DMSO is monomeric but in aqueous
solution the metal-porphyrins readily dimerize at concentrations
of 1–2 μM [37]. The aggregation state is generally dimers [38].
Because of this, many investigators routinely employ heme in
an alkaline stock (e.g. 1 M NaOH, pH 11) neutralized in bufferbefore addition to the culture medium of cells. We found that the
inhibitory effects of heme solubilized in DMSO (protoH/
DMSO) on WST-1/mPMS reduction are significantly higher
that that of heme from an alkaline stock neutralized before use
(protoH/b). The data from several combined experiments each
carried out in triplicate are shown in Fig. 2C. Similar differences
are also seen for mesoheme. These data are consistent with the
expected differences in physical state and support the view that
the monomer is the biologically active form.
To investigate the role of the redox-active metal in the
inhibition of WST-1/mPMS reduction, the effects of heme (i.e.
iron-protoporphyrin IX) were compared with gallium proto-
porphyrin IX (GaPP) a heme analog with a redox inert metal.
Unlike protoheme and mesoheme, GaPP had little effect on
WST-1/mPMS reduction with only a slight inhibition at the
highest concentration, 5 μM (Fig. 3A). Similarly, tin Sn(IV)
protoporphyrin IX (SnPP) was not an effective inhibitor (Fig.
3A). These data provide evidence that a redox-active iron is
required for the interaction between heme and the PMET WST-
1/mPMS reduction system. We also investigated the role of the
carboxyl groups on the C and D rings of deuteroheme by com-
paring the effects of deuteroheme with iron deuteroporphyrin IX
dimethyl ester (see structures in Fig. 1; deuteroheme contains
hydrogen atoms instead of vinyl groups at positions 2 and 4 of
the porphyrin ring). Deuteroheme ester did not affect WST-1/
mPMS reduction, whereas deuteroheme was inhibitory, impli-
cating a role for carboxyl groups in the interaction of heme with
PMET by cells (Fig. 3B). Of the three heme analogs, deutero-
heme was less inhibitory than meso- and protoheme, suggesting
that the side chain in positions 2 and 4 affects the interaction with
cells.
As additional controls, the effects of metal-free porphyrins on
PMET were also investigated first using protoporphyrin IX
(PPIX). Unexpectedly, PPIX/DMSO inhibited WST-1/mPMS
reduction although to a lesser extent than protoheme at theore-
tically equivalent molar concentrations: ca. 25% v. 75% at 5 μM
(Fig. 4A). Protoporphyrin IX, like heme and heme analogs, is
not water soluble [37]. One of the most water-soluble porphyrins
is deuteroporphyrin IX (Fig. 1C). Not only was deuteropor-
phyrin IX/DMSOmore effective than PPIX at inhibitingWST-1/
mPMS reduction but deuteroporphyrin/buffer had similar inhi-
bitory effect (data not shown), consistent with its greater solu-
bility in aqueous solution (Fig. 4A). Thus, these data also
support the view that, like the hemes, the physical state of the
porphyrins affects their biological activity. For deuteropor-
phyrin, the Kd for dimerization in phosphate buffered saline
(PBS) is 2.3 μM and for mesoporphyrin, 5.4 μM [37]. Cell free
control experiments are included in Fig. 4. As with heme, the
inhibitory effects of iron deuteroporphyrin IX dimethyl ester and
protoporphyrin IX are lessened when the stock is prepared in
neutralized alkali (data not shown) which results in fewer
monomers.
3.3. Effect of heme–hemopexin on WST-1/mPMS reduction
Heme has been proposed to diffuse across the lipid bilayer of
membranes based on studies in liposomes; and the interaction of
Fig. 2. Heme inhibits WST-1/mPMS reduction by HL60 cells. Panel A: HL60 cells were incubated with: DMSO vehicle (circles; combined data from 10 independent
experiments in triplicate); protoheme/DMSO (triangles; combined data from 10 independent experiments in triplicate); mesoheme/DMSO (inverted triangles;
combined data from 7 independent experiments in triplicate) for 10 min prior to addition of WST-1/mPMS. Absorbance (450 nm) was measured after 45 min and data
shown are mean±S.E.M. There are no significant differences between the extent of inhibition by protoheme and mesoheme over this concentration range (For example
at 5 μM: P=0.2699, 1 μM; P=0.2093 and 0.25 μM: P=0.3018). When HL60 cells were incubated with protoheme and WST-1 alone without the IEA mPMS there
was no reduction of WST-1 (crosses; combined data from 2 independent experiments in triplicate). Similar data were also obtained with mesoheme in the absence of
mPMS (stars; combined data from 2 independent experiments in triplicate). Panel B: mesoheme was incubated with NADH (40 μM)+WST-1/mPMS in the absence of
HL60 cells (squares, dashed line; mean±S.E.M. from two independent experiments carried out in duplicate) or with WST-1/mPMS in the presence of HL60 cells as
described for panel A (inverted triangles, solid line; mean±S.E.M. from combined data from 7 independent experiments in triplicate). When the “no cells" data are
subtracted from the “cells" data, the hyperbolic curve generates a Kd of 221nM. Panel C: HL60 cells were incubated with sodium phosphate buffer (Na2PO4=b), pH
7.4 (open circles, dashed line; combined data from 8 independent experiments in triplicate), protoheme/Na2PO4 (protoH/b; open triangles, dashed line; combined data
from 2 independent experiments in triplicate), or mesoheme/ Na2PO4 (mesoH/b; open inverted triangles, dashed line, combined data from 3 independent experiments
in triplicate) for 10 min prior to addition of WST-1/mPMS. Absorbance (450 nm) was measured after 45 min and data shown are mean±S.E.M.. These data have been
superimposed on the data from Fig. 2A for DMSO stocks. Significant differences in the extent of inhibition between metal-tetrapyrroles in DMSO v. buffer are
apparent over the concentration range 0.25 μM (protoH P=0.0033, mesoH P=0.0166) to 5 μM (protoH P=b0.0001, mesoH P=b0.0001).
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primarily hydrophobic but with some electrostatic character
[39]. When heme is bound to hemopexin, heme uptake takes
place via endocytosis [40]. Specific transmembrane heme
transporters have proved elusive and in our working model a
heme transporter is associated with the heme–hemopexin
receptor for export across the endosome membrane to cytosol.
The best candidate to date for a heme uptake is a low capacity
heme transporter, which is a high affinity folate transporter, theheme carrier protein 1 [27]. We investigated the interaction
between heme–hemopexin and WST-1/mPMS reduction in
HL60 cells. In the presence of live cells, heme–hemopexin
significantly inhibited WST-1/mPMS reduction at concentra-
tions above 8 μM (Fig. 5A). To determine whether heme–
hemopexin is specific for this interaction and whether heme is
required, cells were incubated with equivalent concentrations of
apo-hemopexin. No inhibitory effects were observed except at
10 μM, where there was a 28% inhibition of WST-1/mPMS
Fig. 4. Interaction between metal-free porphyrins and PMET. HL60 cells were
incubated with: DMSO (circles), PPIX/DMSO (filled right side triangles,
combined data from 3 independent experiments), protoheme/DMSO (triangles),
deuteroporphyrin IX/DMSO (filled right side diamonds; combined data from 3
independent experiments) for 10 min prior to addition of WST-1/mPMS.
Absorbance (450 nm) was measured after 45 min and data shown are mean±
S.E.M. Protoporphyrin IX or deuteroporphyrinIX were incubated with NADH
(40 μM)+WST-1/mPMS in the absence of HL60 cells (filled right side triangles
or filled right side diamonds, respectively, dashed line; mean±S.E.M. from two
independent experiments carried out in duplicate).
Fig. 3. Interaction between heme and PMET requires redox-active iron and
carboxyl groups. Panel A: HL60 cells were incubated with: DMSO (circles;
combined data from 12 independent experiments in triplicate), GaPP/DMSO
(filled left side squares; combined data from 2 experiments in triplicate), SnPP/
DMSO (filled right side squares; combined data from 3 experiments in
triplicate), protoheme/DMSO (triangles; combined data from 12 independent
experiments in triplicate), for 10 min prior to addition of WST-1/mPMS.
Absorbance (450 nm) was measured after 45 min and data shown are mean±
S.E.M. Statistical analysis reveals no significant difference between the GaPPIX
and SnPPIX data sets v. DMSO solvent control (e.g. at 0.1 μM, P=0.6662 and
0.9382, respectively and at 5 μM, P=0.8951 and P=0.5064, respectively).
Panel B: HL60 cells were incubated with: DMSO (circles; combined data from
12 experiments in triplicate), mesoheme/DMSO (inverted triangles, combined
data from 8 experiments in triplicate), deuteroheme (diamonds; combined data
from 2 experiments in triplicate), iron deuteroporphyrin IX dimethyl ester/
DMSO (open diamonds; combined data from 4 experiments in triplicate)) for
10 min prior to addition of WST-1/mPMS. Absorbance (450 nm) was measured
after 45 min and data shown are mean±S.E.M. There was no significant
difference between the O.D. 450 nm for deuteroheme ester and DMSO.
Deuteroheme was significantly different from its ester and also from mesoheme
over the concentration range 0.5–5.0 μM.
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heme–hemopexin. Additional cell free controls revealed that
only at the highest concentration of 15 μM was there a small
decrease in the absorbance at 450 nm when heme–hemopexin
was added to NADH and WST-1/mPMS in the absence of cells
(Fig. 5B). Thus, overall these data strongly support that heme–
hemopexin interaction with electrons from PMET of live cells.
3.4. Role for copper in the interaction of heme–hemopexin, but
not exogenous heme, with WST-1/mPMS reduction
The copper chelator, bathocuproine disulfonic acid (BCDS),
prevents induction of both HO-1 and MT mRNA by heme–
hemopexin [41]. Binding to the hemopexin receptor is un-affected since the activation of the RelA/NFκB pathway still
takes place [42] but surface events consistent with the activation
of metal-dependent and Cu(I)-catalyzed redox events do occur.
Notably, these are inhibited by BCDS but not by iron chelators
(or a BCDS–copper complex; ref. [42,43]). Due to the require-
ment for copper-proteins for iron uptake, we therefore investi-
gated whether the inhibition of WST-1/mPMS reduction by
heme–hemopexin was reduced or prevented by BCDS. Data in
Fig. 5A show that when BCDS is added to the medium for
30 min before heme–hemopexin, there is a significant diminu-
tion of the inhibitory effect on WST-1 reduction, supporting a
role for copper at the cell surface in the interaction of heme–
hemopexin with PMET. Significantly, and in contrast, BCDS did
not prevent the decrease in WST-1/mPMS reduction by heme in
HL60 cells (Fig. 5C). Additional controls in the absence of cells
demonstrate that there was no significant decrease in the
absorbance at 450 nm when heme–hemopexin was added to
NADH and WST-1/mPMS, in the presence or absence of BCDS
(10 μM; Fig. 5B). Overall, these data confirm that the effects of
heme–hemopexin on PMET require viable cells and are copper-
sensitive in contrast to the inhibitory effects of exogenous heme.
Reduction of heme–hemopexin complexes generates char-
acteristic red shifts and increases in absorbance in the Sôret
region, α and β peaks [35]. Complexes reduced chemically by
sodium dithionite are stable and remain reduced for up to 15 min
at 2–37 °C (data not shown). This stability would theoretically
allow detection of reduced heme–hemopexin but only if it was
released from cells into the medium in sufficient amounts or to a
large extent. In this assay, release from cells (1×106) of receptor-
bound 40,000 (surface; [31]) or 140,000 (surface and internal
pools estimate) molecules of heme–hemopexin would produce
ca. 6.6×10−11 M or 2.3×10−10 M heme–hemopexin, respec-
tively, which are spectrally undetectable. On the other hand,
complete reduction of 0.5 μM heme–hemopexin or 10% re-
duction of 5 μMheme–hemopexin would produce anOD∼0.07
Fig. 6. Model for the interaction of heme and heme–hemopexin with PMET. The
heme analog studies here indicate that heme occupies, via free carboxyl groups
and interaction with 2,4 substituents, one or more sites on the surface of the
plasmamembrane close to where the oxido-reductases of PMETrelease electrons
to mPMS that then reduce WST-1. Our data support the view that ferri-heme
accepts electrons generated by PMET at the cell surface but does not transfer
them toWST-1. Similarly, heme–hemopexin also accepts electrons generated by
PMET at the cell surface but does not transfer them to WST-1 and, in contrast to
heme, requires copper for these surface events since they are prevented byBCDS.
Subsequently or possibly concurrently, both ferro-heme and ferro-heme–
hemopexin are rapidly internalized into cells but by different routes, e.g. via a
heme transporter and receptor-mediated endocytosis (RME), respectively. We
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spectral changes in either protoheme–hemopexin or meso-
heme–hemopexin in medium samples rapidly removed from
HL60 cells following centrifugation (1 min at 100×g). Cells
were incubated with hemopexin complexes (0.5, 1.0, 2.5,
5.0 μM) for periods of time spanning 5 sec up to 30 min.
Overlays of these spectra revealed an extremely small (e.g. 0.01
OD) but consistent increase in absorbance at ∼550 nm that was
rapidly released (within 1–2 min) from the cells but without any
detectable absorbance in the Sôret region indicating that this was
not due to a molecular heme species. We therefore conclude that
the interaction between heme–hemopexin and PMET generates
receptor-bound ferro-heme–hemopexin; and that the reduced
complex is retained within cells, likely the endosome, and not
released into the medium (Fig. 6).
4. Discussion
In this report, we provide the first clear evidence of an
interaction between electron transport across the plasma mem-
brane and the two physiologically relevant redox-active mole-propose that a physiological mediator is important for reduction of ferri-heme or
ferri-heme hemopexin by PMET, in part because of the copper requirement for
heme–hemopexin on the PMETsystem. With respect to a physiological electron
acceptor analogous to mPMS that could mediate heme and heme–hemopexin
reduction via PMET in vivo we can only surmise possibilities. Pyocyanin and
soluble quinones, as well as PMS, are molecules that are known and act physio-
logically in electron transport in some microorganisms.cules, heme and heme–hemopexin. Thus, heme–hemopexin as
well as proto-, meso- and deutero-heme, but not Ga-PPIX,
inhibit mPMS-mediated WST-1 reduction by live cells. SinceFig. 5. Heme–hemopexin inhibits WST-1 reduction by PMET: copper-
dependence. Panel A: HL60 cells were incubated with: either PBS (filled
triangles); BCDS (open triangles); heme–hemopexin/PBS (filled squares), or
BCDS followed by heme–hemopexin/PBS (open squares) for 10 min prior to
addition of WST-1/mPMS. Absorbance (450 nm) was measured after 45 min.
The data shown are mean and S.E.M. from two independent experiments carried
out in duplicate. BCDS significantly reduced the inhibition by heme-HPX (for
10 μM HHPX P=0.0153 and for 15 μM HHPX Pb0.0001). HHPX: sigmoidal
dose–response R2 = 0.9707 HHPX+BCDS: sigmoidal dose–response
R2=0.9412. Panel B: HL60 cells were incubated with heme–hemopexin/PBS
(filled squares, solid line) as described in panel (A) Heme–hemopexin was
incubated with NADH (40 μM)+WST-1/mPMS in the absence (filled squares,
dashed line; mean±S.E.M. from two independent experiments carried out in
duplicate) or presence (open squares, dashed line; mean±S.E.M. from two
independent experiments carried out in duplicate) of 10 μMBCDS in the absence
of HL60 cells. The inhibition of WST-1/mPMS reduction (O.D. 450 nm) by
HHPX is significantly higher when viable cells are present (no cell v. cells,
P=0.00162 or b0.0001 for 10 and 15 μM HHPX, respectively). Panel C:
HL60 cells were incubated with DMSO (filled circles, solid line), mesoheme as
described in legend to Fig. 2B in the absence (filled inverted triangles, solid line)
or presence of 10 μM BCDS (open inverted triangles, solid line) mean±S.E.M.
from combined data from 7 independent experiments in triplicate). BCDS does
not cause any significant changes in the inhibition by heme of WST-1/mPMS
reduction (mesoH v. mesoH+BCDS P=0.0802 and =0.0810 at 2 and 5 μM,
respectively).Mesohemewas incubatedwithNADH (40 μM)+WST-1/mPMS in
the absence (filled inverted triangle, dashed line; mean±S.E.M. from two
independent experiments carried out in duplicate) or presence of 10 μMBCDS in
the absence of HL60 cells (open inverted triangles, dashed line; mean±S.E.M.
from two independent experiments carried out in duplicate).
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heme–hemopexin are natural substrates for the cell growth-
associated PMET pathway responsible for WST-1 reduction as
depicted in the model shown in (Fig. 6). Our data also show that
neither heme–hemopexin nor heme can replace mPMS as an
intermediate electron acceptor and pass electrons on to WST-1.
Notably WST-1 cannot cross the plasma membrane. We
therefore conclude that heme–hemopexin and heme interact
with electrons emanating from cellular PMET oxidoreductase
enzymes. This may require a cellular physiological mediator
since the interaction between heme–hemopexin and cellular
PMET is sensitive to the copper chelator BCDS whereas that of
heme is unaffected by BCDS.
Inhibition of WST-1 reduction is saturable by heme,
indicating that a finite number of events are involved in the
inhibition at the mPMS concentration employed, possibly
reflecting heme interaction (i.e. binding) sites. By analogy with
enzyme substrate interactions and solute carrier analysis, these
electron acceptor events are of relatively high affinity. From the
combined data for proto- and meso-heme, the Kd (equivalent to
half the concentration at saturation) is estimated at 100–500 nM;
and when the “no cells” data were subtracted from the “with
cells” data (Fig. 2B) the resulting hyperbolic curve generated a
Kd for protoheme of 221 nM. Inhibition is greatest when heme is
dissolved in DMSO, a solvent in which heme is predominantly
monomeric, and significantly less in aqueous solution in which
heme rapidly dimerizes, presumably to non-covalent dimers and
also oxo-μ dimers. We therefore propose that these effects of
heme on PMETare due to monomeric heme. Heme dimerization
is a pH-sensitive process, driven principally by the chemical
nature of the 2,4 substituent groups, and in particular the vinyl
group present in protoporphyrin, the naturally occurring
tetrapyrrole [38]. Due to the inertness of protoheme upon
dimerization, Brown and colleagues [38] proposed two impor-
tant concepts: first, that dimerization may be an evolutionary-
determined protective mechanism for cells against oxidative
damage by monomeric heme; and, second, that a heme dimer
may be converted to a monomer by associating with a protein on
cells. Using Kdimerization= [D][H
+]/[M]2 and pH 7 where [H+] is
1.00E-07, we calculated the proportion of monomer: dimer for
the following molar concentrations: 5×10−9, 5×10−8, 1×10−7,
5×10−7, 1×10−6 and 2×10−6 for the heme and porphyrins that
we have investigated. This concentration range includes those
we used experimentally here. The respective Kdimerization
values used for protoheme, mesoheme, deuteroheme are 4.5,
0.0692 and 0.035 M−1 [38], respectively and for mesopor-
phyrin and deuteroporphyrin 5.4 and 2.3×10−6 M [37].
Protoheme exists as a dimer in aqueous solution but is 78%
monomer at 5×10−9 M. Above 2×10−6 M, both meso and
deuteroheme are dimers, but at 1×10−6 M the proportion of
monomers is ∼31% for both and at 0.5×10−6 M the pro-
portion of monomers is ∼65% and 83%, respectively. In
contrast, meso- and duetero-porphyrins are monomeric over
this concentration range.
Also, the data derived from the two heme analogs, SnPPIX
and GaPPIX, containing metals that vary in their ability to be
reversibly oxidized and reduced support the view that a redox-active metal such as iron is required for the inhibitory effects of
heme on PMET. Consistent with the electrostatic component
described [39] heme may occupy a site via its carboxyl groups
since the iron deuteroporphyrin IX dimethyl ester is inactive
whereas deuteroheme is inhibitory. An alternative explanation
based on redox potentials is that the heme ester is harder to
reduce. There is an unusual negative 300 mV difference in redox
potential between mesoheme ester and its free acid (at least
measured in pyridine solution 0.399 V cf. 0.096 V due to the low
water-solubility of both molecules; ref. [44]). An analogous
difference in redox potential is likely between deuteroheme and
its ester. Several scenarios can be envisaged. Either the ester does
not bind to the putative heme site, or if it does bind it cannot be
reduced. In this latter case, the electrons from cells find another
pathway to WST-1 since the ester does not inhibit WST-1
reduction. Our overall conclusion is that heme is reduced by
electrons generated by cells via PMET. A prioriwe do not know
whether the direct electron donor for heme is a PMET enzyme
component or complex, or the mPMS radical reduced by cells.
Current studies are aimed at investigating how PMET is linked
with heme uptake by cells since copper is required for the
induction of HO-1 by heme–hemopexin [42,45], which is
prevented by nutritional copper deficiency (K.R. Rish and
A. Smith, unpublished data), and copper has been linked with
redox active events at the cell surface (i.e. carbonyl production)
in response to heme–hemopexin [42]. Overall, we conclude
from our data that there is a specific effect of BCDS that results
in an alteration of the ability of heme–hemopexin to pick up
electrons from cells. This inhibitory effect of BCDS on the
effects of heme–hemopexin on PMET represents a third link
between copper at the cell surface and heme–hemopexin.
ECTO-NOX proteins have a copper binding site and CNOX
from soybean loses activity if denatured and refolded in the
presence of BCDS [46]. It is not known whether BCDS removes
copper from native CNOX. Apo-hemopexin, has been proposed
to function as a metal binding protein including copper, nickel
and the affinity has been characterized for manganese {[K(A)=
(15±3)×10(6) M(−)(1) and K(A) b/=2×10(3) M(−)(1) [47]}.
However, given that the physiological levels of copper in plasma
are 20 μM [48,49] whether, or to what extent, these sites are
occupied under normal physiological conditions remains to be
established. There may be a localized concentration of copper at
the cell surface, perhaps Cu(I) for uptake via Ctr1, available to
BCDS.
For electron transfer to take place between redox centers, they
must be physically close to each other and the redox potentials
must also be within a suitable range. Several factors affect the
redox potential of a redox center like heme including its im-
mediate environment (i.e. protein and solvent exposure). It is
established that the axial ligands of heme and heme analogs play
amajor role in controlling redox potentials due to their electronic
effects on the metal centre. For example, the observed E1/2 value
for heme when bound to hempexin is approximately 100 mV
less positive {M. Flaherty, A. Smith and A. Crumbliss, manu-
script submitted}. In addition, exposure in vivo to solvent or a
hydrophobic environment within a protein or lipid bilayer affects
the redox potential as does the presence of cations and anions.
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hemopexin, which is expected to affect the redox potential of this
complex. By analogy with iron-transferrin, receptor binding will
shift the redox potential to make it easier to reduce the complex.
For iron-transferrin, receptor binding at low pH facilitates Fe3+/
Fe2+ reduction, leading to the proposal that for this complex iron
reduction is the likely initial step for iron release in the endosome
[50].
Unexpectedly, two porphyrins also inhibited WST-1/mPMS
reduction by cells but to varying extents. Protoporphyrin was
significantly less inhibitory than protoheme, whereas the water-
soluble deuteroporphyrin was even more inhibitory than proto-
heme even at very low concentrations (0.1–0.25 μM). The
porphyrin macrocycle can be reduced but a very strong reductant
would normally be required and such reduction can generate a
free radical. The redox potentials for porphyrins are only
available using non-biological solvents, e.g. deuteroporphyrin
IX in DMSO (−1.29 V), PPIX in DMSO (−1.16 V),
mesoporphyrin IX in DMSO (−1.34 V; ref. [51]). However,
these values clearly reveal that porphyrins are more difficult to
reduce than heme and heme analogs which can vary between
+70 mV and −200 mV [44,52]. We therefore propose that
porphyrins occupy sites near the cell surface close to where
mPMS is reduced and, thus, physically prevent electron transfer
from cells to mPMS or from mPMS to WST-1, rather than
reduction taking place at the level of the porphyrin ring.
Heme–hemopexin induces HO1 mRNA in HL-60 cells [32]
and is reported to incorporate heme into myeloperoxidase [31].
Thus, these data support the view that HL60 cells take up heme
from heme–hemopexin complexes as shown in vivo for liver
[53,54] and also for cultured hepatocytes [55] and hepatoma
cells [34]. Here, we show that heme–hemopexin inhibits the
reduction of WST-1 by cells; that this inhibition is prevented by
the copper chelator, BCDS, and that heme–hemopexin does not
replace the IEA, mPMS, in the assay. Once more the most
compelling evidence for a direct interaction of heme–hemo-
pexin with PMET are the differences between the effects of
heme–hemopexin on WST-1/mPMS reduction in the presence
and absence of cells, which support the view that heme–
hemopexin is reduced by electrons donated by living cells.
BCDS prevents induction of HO1 mRNA [41] by heme–
hemopexin, as well as some, but significantly not all, of the
regulatory effects of hemopexin. BCDS inhibits the nuclear
translocation of MTF1 a transcription factor for metallothionein
regulation but not that of RelA/NFκB [42]. BCDS also inhibits
surface redox active events activated by heme–hemopexin [43].
Importantly, binding of heme–hemopexin to its receptor is not
affected by BCDS since the binding and endocytosis of
fluorescently-tagged heme–hemopexin, viewed by immuno-
fluorescence microscopy, is unaffected by incubation of cultured
cells with BCDS (R. Helston and A. Smith, unpublished data).
Two processes of heme uptake from hemopexin have been
defined in isolated rat hepatocytes: a high affinity, low capacity
system that has been termed specific, and a low affinity, high
capacity system termed selective [55]. Based on the concentra-
tion of heme–hemopexin required to half maximally inhibit
WST-1/mPMS reduction, reduction appears to be linkedwith theselective heme uptake process. This is currently under in-
vestigation. BCDS also distinguishes between the effects of
exogenous heme and heme–hemopexin on WST-1/mPMS
reduction by living cells suggesting that the interaction of
these twomolecules with cells is different. Such a concept is also
consistent with the lack of competitive inhibition by exogenous
free heme of heme uptake from [59Fe]heme–hemopexin in
contrast to unlabeled heme–hemopexin [55], which is an
effective competitive inhibitor. Since reduced heme–hemopexin
is reasonably stable in vitro at 37 °C and physiological pH, and
could not be detected after incubation with cells, we propose that
it remains bound to the receptor for subsequent steps in
endocytosis. Interactions between the heme moiety of recep-
tor-bound heme-HPX and the heme transporter for heme export
from endosomes is likely due to the poor solubility of heme and
its chemical reactivity. In conclusion, this is the first evidence
that heme and heme–hemopexin interact with PMET and are
likely reduced by electrons generated via cell surface NADH
oxidoreductases. The steps involved have been presented in
diagrammatic form in Fig. 6. We therefore propose that heme
and heme–hemopexin may be natural substrates for PMET or
may interact with a cellular physiological mediator via PMET.
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